Cargando…

CAR T Cells: A Snapshot on the Growing Options to Design a CAR

Adoptive cell therapy of malignant diseases with chimeric antigen receptor (CAR) modified T cells rapidly advanced from pre-clinical models to commercial approvals within 2 decades. CARs redirect patient's T cells towards cancer cells and activate the engineered cells for a cytolytic attack res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holzinger, Astrid, Abken, Hinrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745938/ https://www.ncbi.nlm.nih.gov/pubmed/31723811 http://dx.doi.org/10.1097/HS9.0000000000000172

Ejemplares similares

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

CAR's made it to the pancreas
por: Chmielewski, Markus, et al.
Publicado: (2012)

Do Treg Speed Up with CARs? Chimeric Antigen Receptor Treg Engineered to Induce Transplant Tolerance
por: Kaljanac, Marcell, et al.
Publicado: (2022)

CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation
por: Barden, Markus, et al.
Publicado: (2023)

IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Nanobody Based Dual Specific CARs
por: De Munter, Stijn, et al.
Publicado: (2018)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy
por: Paasch, Daniela, et al.
Publicado: (2022)

Most Do, but Some Do Not: CD4(+)CD25(−) T Cells, but Not CD4(+)CD25(+) Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
por: Hombach, Andreas A., et al.
Publicado: (2017)

IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells
por: Hombach, Andreas A., et al.
Publicado: (2020)

S80. Prolongation of T cell response by OX40 co-signalling CARS
por: Abken, H
Publicado: (2014)

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts
por: Tóth, Gábor, et al.
Publicado: (2020)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
por: Ambrose, Christine, et al.
Publicado: (2021)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors
por: Hombach, Andreas, et al.
Publicado: (2022)

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer
por: Hombach, Andreas A., et al.
Publicado: (2023)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
por: Műzes, Györgyi, et al.
Publicado: (2023)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Making CAR T Cells a Solid Option for Solid Tumors
por: Schmidts, Andrea, et al.
Publicado: (2018)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

CAR-T design: Elements and their synergistic function
por: Jayaraman, Jayapriya, et al.
Publicado: (2020)

Application and Design of Switches Used in CAR
por: Głowacki, Paweł, et al.
Publicado: (2022)

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
por: Ciulean, Ioana Sonya, et al.
Publicado: (2023)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model
por: Alzubi, Jamal, et al.
Publicado: (2020)

CAR models: next-generation CAR modifications for enhanced T-cell function
por: Abate-Daga, Daniel, et al.
Publicado: (2016)

Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir
por: Patasic, Lea, et al.
Publicado: (2020)

Expression of TRX1 optimizes the antitumor functions of human CAR T cells and confers resistance to a pro-oxidative tumor microenvironment
por: Balta, Emre, et al.
Publicado: (2022)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i6pi2lkfi6skln9kikgbs9u9br